At 12 years of testosterone treatment, HbA1c decreased to 5.5±0.3%.
Low adherence to topical testosterone therapy has been linked to lowered total testosterone values and poor outcomes.
There has been growing concern that testosterone replacement therapy is associated with adverse cardiovascular outcomes.
Studies published in JAMA and JAMA Internal Medicine highlight the benefits and risks of treating men for low testosterone.
Researchers have pinpointed harmonized references ranges for total testosterone levels in men.
Starting testosterone treatment is associated with an increased risk of venous thromboembolism (VTE), peaking within 6 months and declining thereafter.
Men treated with implantable testosterone pellets have a statistically significant increase in mean hematocrit, but it is unlikely to be clinically relevant.
Once-daily testosterone solution 2% (T-sol) is safe and improves sex drive and energy in men with androgen deficiency.
Once-daily 2% testosterone solution (T-sol) is safe and effective for sex drive and energy in hypogonadal men.
Men using testosterone gel experienced improvements in sex drive, sexual activity, and erectile function.
Endocrinology Advisor Articles
- Maternal Deaths in the United States: Sounding a Call to Action
- Semaglutide Improved Beta-Cell Function and Glycemic Control in Type 2 Diabetes
- Blood Glucose Self-Monitoring in Type 2 Diabetes Does Not Benefit Glycemic Control
- Major Cardiovascular Event Incidence in T2D: Degludec vs Glargine
- The Handoff: Your Week in Endocrinology News - 6/23/17
- Reduced Cardiovascular Events in Type 2 Diabetes Treated With Dapagliflozin
- Canagliflozin Reduces Cardiovascular Stress In Older Patients With Type 2 Diabetes
- Diabetic Retinopathy Caused by Sleep Apnea in T2D
- Transition-of-Care Algorithm Performs Well in Surgery Patients With Type 2 Diabetes
- GLP-1 Analog Counteracts Antipsychotic-Induced Glucose Intolerance, Weight Gain